| 32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for cancer, and cardiovascular, metabolic and psychiatric disorders. | |
| | |
MedLine Citation:
|
PMID: 20721818 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on Hsp90 inhibitors and Hsp70 inducers, such as KU-32 and KU-174 (University of Kansas); natural products in drug design, such as minnelide (University of Minnesota) and tylocrebrine; novel compounds from Merck for metabolic and cardiovascular diseases, such as MK-7725, a series of DDP4 inhibitors and KV1.5 ion channel antagonists; and the discovery of the VEGFR2 kinase inhibitor AMG-429 (Amgen Inc). |
| | |
Authors:
|
Deborah Gater |
Related Documents
:
|
20491598 - Roots, development and future directions of laboratory medicine. 16037858 - Medicinal chemistry--16th international symposium. 18-22 september 2000, bologna, italy. 18938148 - Will "personalized medicine" need personalized laboratory approach? 10420218 - The role of transfusion medicine physicians. a vanishing breed? 3786748 - Low-osmolality contrast media: premises and promises. 21276958 - Medical and psychosocial complications associated with method of bladder management aft... |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: IDrugs : the investigational drugs journal Volume: 13 ISSN: 2040-3410 ISO Abbreviation: IDrugs Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-19 Completed Date: 2010-12-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883655 Medline TA: IDrugs Country: England |
Other Details:
|
Languages: eng Pagination: 517-9 Citation Subset: IM |
Affiliation:
|
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. deborah.gater@thomsonreuters.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cardiovascular Diseases / drug therapy* Drug Design Drugs, Investigational / therapeutic use* HSP70 Heat-Shock Proteins / agonists HSP90 Heat-Shock Proteins / antagonists & inhibitors Humans Kv1.5 Potassium Channel / antagonists & inhibitors Mental Disorders / drug therapy* Metabolic Diseases / drug therapy* Neoplasms / drug therapy* Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Drugs, Investigational; 0/HSP70 Heat-Shock Proteins; 0/HSP90 Heat-Shock Proteins; 0/Kv1.5 Potassium Channel; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for neurodegeneration,...
Next Document: Cell-based assays--Informa Life Sciences' Fifth Annual Conference--Cell-based assays for compound sc...